NAD+ Precursors Are Disease-State Interventions, Not Universal Longevity Drugs — The Baseline Deficit Hypothesis

The core claim: NAD+ precursors (NMN, NR) produce meaningful functional benefits primarily in organisms with pre-existing NAD+ deficits from disease or advanced aging, and will fail to extend lifespan in healthy, well-nourished populations. Their therapeutic value is real but narrower than the longevity field currently assumes.

The evidence pattern is consistent. In preclinical models, NMN extends median lifespan by approximately 8.5% in male mice, with sex-dependent and tissue-specific effects—females show greater lifespan extension while males benefit more in late-life metabolic parameters. Benefits concentrate in skeletal muscle, brain, liver, and adipose tissue where age-related NAD+ decline is most severe.

But the human clinical data tells a different story. While NR and NMN safely elevate blood NAD+ levels (one trial showed 67% increase vs 4% placebo), functional improvements in healthy aging populations are modest and inconsistent. Skeletal muscle NAD+ levels do not reliably increase with oral supplementation, and strength gains remain elusive. The transcriptomic changes are there—NR modulates muscle gene expression—but the phenotypic translation is weak.

Contrast this with disease contexts: NR in Parkinson patients increased brain and CSF NAD+, reduced inflammatory cytokines, and upregulated mitochondrial and lysosomal pathways. Heart failure patients showed improved mitochondrial function and reduced proinflammatory factors. The signal is strongest where the deficit is deepest.

This pattern suggests a ceiling effect. In healthy individuals with adequate NAD+ biosynthesis, exogenous precursors hit diminishing returns—the salvage pathway is already sufficient, and excess NAD+ may be rapidly metabolized or compartmentalized away from therapeutic targets. The bioavailability problem compounds this: oral NMN and NR may not reach intracellular compartments in tissues like skeletal muscle at sufficient concentrations.

Additionally, some NAD+ precursor variants like NRH may upregulate inflammatory markers in specific immune cell populations, raising concerns about chronic supplementation in immunologically healthy individuals.

My hypothesis: future NAD+ clinical trials should stratify participants by baseline NAD+ status and inflammatory burden. I predict that individuals with measurably depleted NAD+ (>40% below young adult reference) will show significant healthspan benefits, while those with normal NAD+ levels will show no meaningful improvement over placebo. This reframes NAD+ precursors as precision geriatric medicine rather than universal longevity supplements—still valuable, but targeted.